Profound Medical Corp.
PROF evidence brief
What we can confirm
- BioSniper Score:
- 8.1 / 10
- Market Cap:
- $214.1M
- Lead Asset:
- sonalleve (Approved)
What it means
What to watch
Prepared research question
What matters most for PROF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PROF
Profound Medical Corp. is a commercial-stage medical device company developing and marketing AI-powered, MRI-guided, incision-free ablation therapies, primarily TULSA-PRO for prostate disease and Sonalleve for uterine fibroids and other soft-tissue indications.
Key risk: Recurring losses and accumulated deficit
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$214.1M
Cash Runway
—
Lead Asset
sonalleve (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Profound Medical Corp..
Profound Medical Corp. is a commercial-stage medical device company developing and marketing AI-powered, MRI-guided, incision-free ablation therapies, primarily TULSA-PRO for prostate disease and Sonalleve for uterine fibroids and other soft-tissue indications.
- Cash and equivalents of $38.3M as of 2026-06-30 [sec].
- Total revenue of $2.5M and net loss of -$9.5M for the six months ended June 30, 2026 [sec].
- Shareholders' equity of $49.8M and total debt of $9.0M as of 2026-06-30 [sec].
- Accumulated deficit of $279.6M through September 30, 2025 [sec_mda · as of 2025-11-13].
- Exclusive distribution agreement for TULSA-PRO and Sonalleve in Saudi Arabia signed November 2025 [news · published 2025-11-11].
What works
- Two FDA-cleared commercial products (TULSA-PRO and Sonalleve) addressing large markets in prostate disease and uterine fibroids [pipeline].
- Expanding geographic reach via exclusive distribution agreement in Saudi Arabia, the largest healthcare market in the Middle East [news · published 2025-11-11].
- Integration of AI-powered modules (TULSA-AI Volume Reduction for BPH) and exploration of PSMA PET molecular imaging to enhance ablation planning [news · published 2025-11-28][news · published 2026-05-14].
- Management expects existing cash and product sales to fund operations for at least the next 12 months from August 2026 [sec_mda · as of 2026-08-06].
What to weigh
- Recurring operating losses and accumulated deficit of $279.6M through September 30, 2025 [sec_mda · as of 2025-11-13].
- Cash burn: cash decreased from $59.7M (Dec 31, 2025) to $38.3M (Jun 30, 2026) [sec_mda · as of 2026-08-06].
- Dependence on additional financing to fund R&D and expansion; may require additional capital [sec_mda · as of 2026-08-06].
- Foreign exchange risk: cash holdings negatively impacted by changes in non-USD currency rates [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash of $38,271 compared to $59,723 as of December 31, 2025.”
SEC MD&A · August 6, 2026
Accumulated deficit through September 30, 2025
“We have historically experienced recurring losses from operations and have incurred an accumulated deficit of $279,566 through September 30, 2025.”
SEC MD&A · November 13, 2025
Exclusive distribution agreement in Saudi Arabia
“Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia”
News · November 11, 2025
Expectation to fund operations for at least 12 months
“Based on our current operating plans, we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of these unaudited consolidated financial statements.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-08-06 · Earnings: Regulation FD Disclosure – Q2 2026 financial results — Company plans to release second quarter financial results after market close on August 6, 2026.
Risks & what to watch (4)›
Key risks
- Recurring losses and accumulated deficit — Accumulated deficit of $279.6M through Sep 30, 2025; net loss of $9.5M in H1 2026 [sec_mda · as of 2025-11-13][sec].
- Cash burn and need for financing — Cash decreased from $59.7M (Dec 2025) to $38.3M (Jun 2026); may require additional capital [sec_mda · as of 2026-08-06].
- Dependence on product adoption — Cash requirements depend on market acceptance of TULSA-PRO and Sonalleve [sec_mda · as of 2026-08-06].
- Foreign exchange exposure — Non-USD cash holdings decreased due to unfavorable currency rate changes [sec_mda · as of 2026-05-07].
What to watch
- Q2 2026 financial results release expected after market close on August 6, 2026 [catalyst].
- Commercial adoption of TULSA-PRO and Sonalleve in Saudi Arabia following the exclusive distribution agreement [news · published 2025-11-11].
- Launch and clinical data from AI-powered BPH module (TULSA-AI Volume Reduction) [news · published 2025-11-28].
- Integration of TULSA-PRO with PSMA PET molecular imaging for enhanced ablation planning [news · published 2026-05-14].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Profound Medical Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Profound Medical Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.25 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 11, 2026- % of float
- 6.5%
- Days to cover
- 9.9
- Shares short
- 2,091,784
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PROF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Profound Medical Corp.?
Profound Medical Corp. is a commercial-stage medical device company developing and marketing AI-powered, MRI-guided, incision-free ablation therapies, primarily TULSA-PRO for prostate disease and Sonalleve for uterine fibroids and other soft-tissue indications.
What is Profound Medical Corp.'s lead drug candidate?
Profound Medical Corp.'s most advanced tracked candidate is sonalleve (Approved) for Uterine fibroids, adenomyotic tissue, bone metastases pain, osteoid osteoma, and benign desmoid tumors.
Who is the CEO of Profound Medical Corp.?
Dr. Arun Swarup Menawat MBA, Ph.D. is the chief executive officer of Profound Medical Corp. (PROF).
Where is Profound Medical Corp. headquartered?
Profound Medical Corp. (PROF) is headquartered in Mississauga, ON, Canada.
What therapeutic areas does Profound Medical Corp. focus on?
Profound Medical Corp. develops therapies across Oncology, Pain, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.